Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Oral AL3810 (Lucitanib) in Advanced Gastric, Hepatocellular, or Nasopharyngeal Carcinoma
NCT03260179Phase 1Unknown
- Sponsor
- Haihe
- Start
- Aug 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lucitanib in Gastric carcinoma (GC), hepatocellular carcinoma (HCC) and nasopharyngeal carcinoma (NPC) (3 arms), sponsored by Haihe. Primary endpoint: Adverse Events at 1 year. Status: unknown.
02
Drugs
lucitanib
03
Conditions
Gastric carcinoma (GC)hepatocellular carcinoma (HCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03260179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03260179.